Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5

Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5–40 years of age

Published:2024-02 Issue:4 Volume:42 Page:844-852
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Kumwichar Ponlagrit^ORCID,Chongsuvivatwong Virasakdi^ORCID,Vasoppakarn Sanya^ORCID,Atthakul Narumol^ORCID,Nakhonsri Vorthunju^ORCID,Ngamphiw Chumpol^ORCID,Khunkham Peerapat^ORCID,Janpoung Watcharapot^ORCID,Tongsima Sissades^ORCID

Funder

National Institute of Allergy and Infectious Diseases

Fogarty International Center

National Institutes of Health

Publisher

Elsevier BV

Reference39 articles.

1. Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Our World in Data. https://ourworldindata.org/coronavirus; 2023 [accessed 14 December 2023].

2. World Health Organization. Background Document on the mRNA Vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: Background Document to the WHO Interim Recommendations for Use of the Pfizer–BioNTech COVID-19 Vaccine, BNT162b2, under Emergency Use Listing, 14 January 2021. Geneva: World Health Organization; 2021.

3. World Health Organization. mRNA-1273 Vaccine (Moderna) against COVID-19 Background Document: Draft Prepared by the Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines, 19 January 2021. Geneva: World Health Organization; 2021.

4. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

5. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 vaccination and the risk of autoimmune diseases: a Mendelian randomization study;Frontiers in Public Health;2024-03-14